ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR
ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR
ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR 性质
| 沸点 | 1828.5±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.339±0.06 g/cm3(Predicted) |
| 储存条件 | -15°C |
| 溶解度 | 不溶于乙醇；不溶于水； DMSO 中≥135.2 mg/mL |
| 酸度系数(pKa) | 3.19±0.10(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米白色 |
| 序列 | Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr |
ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR 用途与合成方法
Insulin secretion
Glucagon (19-29), from 0.1 pM to 1 nM, exerts a potent negative inotropic action. The most striking observation is a 45% increase in the amplitude of cell contractility elicited by the combination of 30 nM glucagon with 1 nM Glucagon (19-29).
Glucagon (19-29), also named Miniglucagon, is the COOH-terminal (19-29) fragment processed from glucagon. Glucagon (19-29) dose-dependently inhibits insulin secretion stimulated by 8.3 M glucose, with no change in the perfusion flow rate. A concentration of 1 nM Glucagon (19-29) has a significant inhibitory effect on a 1 nM glucagon-like peptide 1 (7-36) amide–potentiated insulin secretion. Glucagon (19-29) is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca 2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein.
ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-P0150 | ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR | 64790-15-4 | 5mg | 420 |
| 2026-09-15 | HY-P0150 | ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR | 64790-15-4 | 10mg | 600 |
